Prostate-specific antigen (PSA) levels in men with Prader-Willi syndrome

IF 1.6 4区医学 Q4 CELL BIOLOGY

Growth Hormone & Igf Research Pub Date : 2024-04-21 DOI:10.1016/j.ghir.2024.101593

Anna Oskarsson , Charlotte Höybye

{"title":"Prostate-specific antigen (PSA) levels in men with Prader-Willi syndrome","authors":"Anna Oskarsson , Charlotte Höybye","doi":"10.1016/j.ghir.2024.101593","DOIUrl":null,"url":null,"abstract":"<div><p>Prader-Willi syndrome (PWS) is a rare genetic disorder typically characterized by body composition abnormalities, hyperphagia, behavioral challenges, cognitive dysfunction, and hormone deficiencies. Hypogonadism is common but knowledge on potential side effects of testosterone replacement is limited, in particular, the long-term effects on behavior and PSA.</p></div><div><h3>Patients and methods</h3><p>Retrospective case studies of seven men, median age 46 years, with genetically verified PWS, testosterone treated hypogonadism and available PSA values were included. Long-term follow-up of PSA was accessible in four patients. Medical records were reviewed for adverse effects.</p></div><div><h3>Results</h3><p>Five men were treated with intramuscular testosterone undecanoate, two had no hypogonadism. Median PSA was 0.68 μg/L (0.23–1.3), median testosterone 15 nmol/L. After a median time of 17 years of testosterone replacement median PSA was 0.75 μg/L (range 0.46–1.4). Testosterone replacement was well tolerated, and no major behavioral changes were reported. Five were treated with growth hormone for >20 years.</p></div><div><h3>Conclusion</h3><p>Levels of PSA were low. Long-term treatment with testosterone was working well and did not result in any clinically meaningful increase in PSA. Our results indicate that testosterone replacement is neither associated with serious adverse events regarding changes in behavior or effect on PSA. However, larger studies are needed to confirm our results.</p></div>","PeriodicalId":12803,"journal":{"name":"Growth Hormone & Igf Research","volume":"76 ","pages":"Article 101593"},"PeriodicalIF":1.6000,"publicationDate":"2024-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Growth Hormone & Igf Research","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1096637424000236","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CELL BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Prader-Willi syndrome (PWS) is a rare genetic disorder typically characterized by body composition abnormalities, hyperphagia, behavioral challenges, cognitive dysfunction, and hormone deficiencies. Hypogonadism is common but knowledge on potential side effects of testosterone replacement is limited, in particular, the long-term effects on behavior and PSA.

Patients and methods

Retrospective case studies of seven men, median age 46 years, with genetically verified PWS, testosterone treated hypogonadism and available PSA values were included. Long-term follow-up of PSA was accessible in four patients. Medical records were reviewed for adverse effects.

Results

Five men were treated with intramuscular testosterone undecanoate, two had no hypogonadism. Median PSA was 0.68 μg/L (0.23–1.3), median testosterone 15 nmol/L. After a median time of 17 years of testosterone replacement median PSA was 0.75 μg/L (range 0.46–1.4). Testosterone replacement was well tolerated, and no major behavioral changes were reported. Five were treated with growth hormone for >20 years.

Conclusion

Levels of PSA were low. Long-term treatment with testosterone was working well and did not result in any clinically meaningful increase in PSA. Our results indicate that testosterone replacement is neither associated with serious adverse events regarding changes in behavior or effect on PSA. However, larger studies are needed to confirm our results.

查看原文本刊更多论文

患有普拉德-威利综合征的男性的前列腺特异性抗原（PSA）水平

普拉德-威利综合征（Prader-Willi Syndrome，PWS）是一种罕见的遗传性疾病，其典型特征是身体成分异常、多食、行为障碍、认知功能障碍和激素缺乏。性腺功能减退症很常见，但有关睾酮替代潜在副作用的知识却很有限，尤其是对行为和 PSA 的长期影响。患者和方法回顾性病例研究纳入了七名男性患者，中位年龄 46 岁，经基因验证患有 PWS，接受过睾酮治疗性腺功能减退症，并有 PSA 值。对四名患者进行了 PSA 长期随访。对医疗记录进行了审查，以了解不良反应。结果五名男性接受了肌肉注射十一酸睾酮治疗，其中两人没有性腺功能减退症。中位 PSA 为 0.68 μg/L (0.23-1.3)，中位睾酮为 15 nmol/L。中位睾酮替代时间为 17 年后，中位 PSA 为 0.75 μg/L（0.46-1.4）。患者对睾酮替代治疗的耐受性良好，未报告有重大行为改变。结论 PSA 水平较低。睾酮的长期治疗效果良好，没有导致任何有临床意义的 PSA 增高。我们的研究结果表明，睾酮替代既不会引起行为改变方面的严重不良事件，也不会影响 PSA。不过，还需要更大规模的研究来证实我们的结果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Growth Hormone & Igf Research 医学-内分泌学与代谢

CiteScore

3.30

自引率

0.00%

发文量

审稿时长

57 days

期刊介绍： Growth Hormone & IGF Research is a forum for research on the regulation of growth and metabolism in humans, animals, tissues and cells. It publishes articles on all aspects of growth-promoting and growth-inhibiting hormones and factors, with particular emphasis on insulin-like growth factors (IGFs) and growth hormone. This reflects the increasing importance of growth hormone and IGFs in clinical medicine and in the treatment of diseases.